Semaglutide Powder CAS 910463-68-2

Semaglutide powde is a novel GLP-1 (glucagon like peptide-1) analogue developed by Dunno and Novo Nordisk. Ozempic is a long-acting dosage form based on the basic structure of liraglutide, which has good efficacy in the treatment of type 2 diabetes. Semaglutide is a GLP-1 analog that was approved by the US Food and Drug Administration in June 2021. Novo Nordisk has completed six pchaseiia studies on Sermaglutide injection and submitted a new drug registration application for weekly injection of Sermaglutide to the US Food and Drug Administration (FDA) on December 5, 2016, as well as a marketing authorization application to the European Medicines Agency (EMA). On the other hand, the daily oral preparation of somalatide is currently in clinical phase III.

Shanxi BLOOM Tech Co., Ltd. has ozempic for sale. If you would like to know about the semaglutide price, please send us an email. Shaanxi BLOOM Tech Co., Ltd. not only provides customized ozempic peptides, but also offers semaglutide with bpc 157. In the chemical industry, both bpc 157 and semaglutide belong to the peptide series, while semaglutide and aod 9604 also belong to the same peptide series. Therefore, Shaanxi BLOOM Tech Co., Ltd. can provide customization. Natural semaglutide is an artificially synthesized GLP-1 analogue with high similarity to natural GLP-1. It was developed by Novo Nordisk to enhance the biological activity and stability of GLP-1 in vivo by simulating its amino acid sequence. Compared with natural GLP-1, Semalutide has a longer half-life and higher biological activity, which makes it a promising drug for the treatment of diabetes.

Semaglutide (trade name: Ozempic) is a drug for the treatment of type 2 diabetes, belonging to insulin like peptide-1 receptor agonist (GLP-1 RA). Chemical formula C187H291N45O59, CAS CAS 910463-68-2. It is a white to almost white powder. It can be dissolved in water and form a transparent to slightly turbid solution. Its solubility in water is about 10 mg/mL, and it can also be dissolved in some organic solvents (such as alcohols and Dimethyl sulfoxide). It is an artificially synthesized peptide like substance. In the chemical structure of peptide semaglutide, there is also a cysteine residue, which is connected with other amino acid residues through disulfide bonds. Relatively stable under conventional drug storage conditions. It can be stored for a long time under refrigeration conditions (2-8 degrees Celsius). The finished drug of this chemical product has many clinical uses, but the products produced by Shaanxi Achieve chem-tech Co.,Ltd. are primary chemical products and are only used for scientific research purposes.

Semaglutide Uses

Semaglutide is an insulin like peptide-1 receptor agonist (GLP-1 RA), which is mainly used to treat type 2 diabetes. In addition to treating diabetes, Semaglutide has also been studied for other potential uses.

1. Treatment of diabetes:

Semaglutide is a long-acting GLP-1 receptor agonist that can lower blood sugar levels by simulating the effects of insulin-like peptide-1 (GLP-1) produced in the body. It can stimulate the secretion of insulin, inhibit the secretion of Glucagon, and slow the emptying speed of gastrointestinal tract, thus reducing the rise of blood sugar after food intake. The long-lasting nature of Semaglutide allows it to be injected once a week to provide continuous blood sugar control.

High Quality Sermaglutide Powder Semaglutide CAS 910463-68-2

2. Weight management:

In addition to treating diabetes, Semaglutide is also used for weight management. Clinical trials have shown that obese patients treated with Semaglutide can significantly reduce weight compared to placebo. Semaglutide works by inhibiting appetite and increasing satiety, thereby reducing energy intake. Therefore, it is considered a potential tool for treating obesity.

3. Cardiovascular protection:

Semaglutide also shows a protective effect on the cardiovascular system. In the cardiovascular safety trial, the risk of cardiovascular events (such as heart attack and stroke) in diabetes patients treated with Semaglutide was significantly lower than that of placebo. This indicates that Semalutide may have the effect of reducing the risk of cardiovascular disease, which may be related to improving insulin resistance, reducing insulin resistance and improving blood fat metabolism.

4. Lipid metabolism disorders:

Semaglutide can also improve lipid metabolism, reduce triglycerides and cholesterol levels in the blood. This is particularly important for patients with diabetes, because they are usually accompanied by abnormal lipid metabolism.

It should be noted that although Semaglutide has been proven to have the aforementioned effects in clinical trials, it still needs to be used under the guidance of a doctor and follow relevant dosage and usage guidelines. In addition, the use of Semaglutide may vary slightly depending on the approval situation in different countries or regions

Pharmacodynamic principle of somaluptide: the interaction between somaluptide and GLP-1 receptor is mediated, increasing cyclic adenosine monophosphate (cAMP), which can stimulate insulin secretion in a glucose concentration-dependent mode and reduce excessive glucagon secretion in a glucose concentration-dependent mode. Therefore, insulin secretion is stimulated when blood glucose rises and glucagon secretion is inhibited. In contrast, liraglutide reduces insulin secretion during hypoglycemia without affecting glucagon secretion. Somalutide could also slightly prolong the gastric emptying time, and the dosage was 3mg without QTc prolongation. In vitro experiments confirmed that somaluride did not inhibit or induce CYP enzymes, nor did it interact with drug transporters. Somaluptide can cause delayed gastric emptying. When used with oral drugs, it can reduce the absorption rate and degree of oral medications. There is no interaction between somalutide, metformin, atorvastatin, warfarin, digoxin, and oral contraceptives.

The synthesis method of somaluptide powder comprises the following steps: (1) synthesis of 6 peptide fragment sequences protected by side chains; (2) The sequence of each peptide fragment was gradually coupled in the solid phase to obtain a fully protected somaluride linear peptide. This method has high purity, high yield, and low cost.

Somaluptide has a broad market. As one of the top ten chronic diseases in the world, diabetes is a metabolic disease characterized by chronic hyperglycemia. Diabetes patients mainly type II patients, and type II diabetes patients account for more than 90%. According to the International Diabetes Federation (IDF) statistics, by the end of 2017, 425million adults worldwide had had diabetes. It is estimated that by 2045, the number of patients worldwide will reach 629million. The prevalence of diabetes in China has exceeded the global average. In 2017, the number of people who have diabetes came 114million. According to the world's top, it is expected to increase to about 150million by 2045.

The naming history of Semaglutide is as follows:

1. Naming of the R&D stage:

Semaglutide is a drug developed by Novo Nordisk, a Danish company. In the development phase, the drug is referred to as NN9535. This is an insulin like peptide-1 receptor agonist, which is used to treat diseases such as diabetes and obesity.

2. Clinical trial stage naming:

Before entering the clinical trial phase, drugs need to be given a temporary name for easy identification and differentiation. During the clinical trial, Semaglutide was named NN9924.

3. Product name:

After clinical trials and obtaining evidence of efficacy, Semaglutide was granted a marketing license and named Ozempic. This name is the trade name of the drug authorized by Novo Nordisk. Ozempic's naming meaning is not very clear, but it may be a unique name designed by Novo Nordisk specifically for the Drug design to distinguish other products and brands.

It should be noted that these designations may not be directly related to the chemical structure, mechanism of action, or characteristics of the drug. These names are mainly used to distinguish and identify drugs in different stages and markets.